POST Online Media Lite Edition


Vermillion elects James T. LaFrance as chairman

Staff writer |
Austin, Tx., USA - December 16, 2013, Austin, Tx., USA - Vermillion, Inc., a molecular diagnostics company, announced James T. LaFrance has been appointed a member of its board and was elected chairman of the board.

Article continues below

Mr. LaFrance has almost 30 years of diagnostic industry experience. Most recently, he was head of digital pathology and acting CEO of Omnyx, LLC for GE Healthcare.

Prior to that, he held a series of commercial, strategic marketing and business development leadership roles at Ventana Medical Systems (now Roche Tissue Diagnostics), including general manager of their North American and International commercial organizations.

Prior to Ventana, he served in leadership roles in strategic marketing and business development at Bayer Diagnostics. He was a member of the board at Mitomics, Inc. from 2010 to 2011.

Mr. LaFrance earned a Bachelor of Arts degree in Economics from the University of Connecticut and an MBA from the University of Notre Dame.


What to read next

Vermillion appoints Eric Varma to board
Vermillion appoints COO
Vermillion adds Peter S. Roddy to the board